Determinants of the efficacy of prophylactic granulocyte transfusions: A meta-analysis

Journal of Clinical Apheresis

Volumn 12, Issue 2, 1997, Pages 74-81

  Vamvakas, Eleftherios C ^a   Pineda, Alvaro A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

Fungal; G ranulocytopenia; Granulocytes; Infection; Leukocytes; Leukopenia; Neutropenia; Neutrophils; Sepsis; Septicemia; Transfusion

Indexed keywords

ACUTE LEUKEMIA; APLASTIC ANEMIA; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; GRANULOCYTE TRANSFUSION; HUMAN; LEUKOCYTE TRANSFUSION; META ANALYSIS; MYCOSIS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL;

BACTERIAL INFECTIONS; HUMANS; LEUKOCYTE TRANSFUSION; MYCOSES;

EID: 0030860867     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1101(1997)12:2<74::AID-JCA4>3.0.CO;2-6     Document Type: Article

References (49)

1. Bensinger WI, Price TH, Dale DC, et al: The effects of daily recombinant human granulocyte colony stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 81:1883-1888, 1993.
2. Caspar CB, Reinhard AS, Burger J, et al: Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony stimulating factor. Blood 81:2866-2871, 1993.
3. McCullough J: Granulocyte transfusion. In Petz LD, Swisher SN, Kleinman S, Spence RK, Strauss RG (eds): "Clinical Practice of Transfusion Medicine," 3rd ed. New York, NY: Churchill Livingstone, 1995, pp 413-432.
4. Strauss RG: Granulocyte transfusions. In: Rossi EC, Simon TL, Moss GS, Gould SA (eds): "Principles of Transfusion Medicine," 2nd ed. Baltimore, MD: Williams and Wilkins, 1995, pp 321-328.
5. Strauss RG: Therapeutic granulocyte transfusions in 1993 (editorial). Blood 81:1675-1678, 1993.
6. Vamvakas EC, Pineda AA: Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apheresis 11:1-9, 1996.
7. Graw RG, Herzig G, Perry S, Henderson ES: Normal granulocyte transfusion therapy. Treatment of septicemia due to gram-negative bacteria. N Engl J Med 287:367-371, 1972.
8. Higby DJ, Yates JW, Henderson ES, Holland JF: Filtration leukapheresis for granulocyte transfusion therapy. Clinical laboratory studies. N Engl J Med 292:761-766, 1975.
9. Fortuny IE, Bloomfield CD, Hadlock DC, Goldwan A, Kennedy BJ, McCullough JJ: Granulocyte transfusion: A controlled study in patients with acute nonlymphocytic leukemia. Transfusion 15: 548-558, 1975.
10. Volger WR, Winton EF: A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia. Am J Med 63:548-555, 1977.
11. Herzig RH, Herzig GP, Graw RG, Bull MI, Ray KK: Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study. N Engl J Med 296: 701-705, 1977.
12. Alavi JB, Root RK, Djerassi I, et al.: A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med 296:706-711, 1977.
13. Winston DJ, Ho WG, Gale RP: Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes. Ann Intern Med 97:509-515, 1982.
14. Schiffer CA, Aisner J, Daly PA, Schimpff SC, Wiernik PH: Alloimmunization following prophylactic granulocyte transfusion. Blood 54:766-774, 1979.
15. Mannoni P, Rodet M, Vernant JP, et al.: Efficiency of prophylactic granulocyte transfusions in preventing infections in acute leukemia. Blood Transf Immunohematol 22:503-518, 1979.
16. Strauss RG, Connett JE, Gale RP, et al.: A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukemia. N Engl J Med 305: 597-603, 1981.
17. Sutton DMC, Shumak KH, Baker MA: Prophylactic granulocyte transfusions in acute leukemia. Plasma Ther Transfus Technol 3:45-50, 1982.
18. Ford JM, Cullen MH, Roberts MM, Brown LM, Oliver RTD, Lister TA: Prophylactic granulocyte transfusions: Results of a randomized controlled trial in patients with acute myelogenous leukemia. Transfusion 22:311-316, 1982.
19. Gomez-Villagran JL, Torres-Gomez A, Gomez-Garcia P, Martinez-Guibelalde F, Velasco-Jimena F: A controlled trial of prophylactic granulocyte transfusions during induction chemotherapy for acute nonlymphoblastic leukemia. Cancer 54:734-738, 1984.
20. Clift RA, Sanders JE, Thomas ED, Williams B, Buckner CD: Granulocyte transfusions for the prevention of infection in patients receiving bone marrow transplants. N Engl J Med 298: 1052-1057, 1978.
21. Winston DJ, Ho WG, Young LS, Gale RP: Prophylactic granulocyte transfusions during human bone marrow transplantation. Am J Med 68:893-897, 1982.
22. Buckner CD, Clift RA, Thomas ED, et al.: Early infectious complications in allogeneic marrow transplant recipients with acute leukemia: Effects of prophylactic measures. Infection 11:243-250, 1983.
23. Ford JM, Cullen MH: Prophylactic granulocyte transfusions. Exp Hematol 5 (Suppl.):65-72, 1977.
24. Buckner CD, Clift RA, Sanders JE, Thomas ED: The role of a protective environment and prophylactic granulocyte transfusions in marrow transplantation. Transplant Proc 10:255-257, 1978.
25. Colditz GA, Miller JN, Mosteller F: How study design affects outcomes in comparisons of therapy: I. Medical. Stat Med 8:441-454, 1989.
26. Cooper H, Hedges LV (eds): "The Handbook of Research Synthesis." New York: Russell Sage Foundation, 1994.
27. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986.
28. Fleiss JL, Gross AJ: Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: A critique. J Clin Epidemiol 44:127-139, 1991.
29. Devine P, Goldstein R, Linden JV, Postoway N, Hoffstadter LK, Hines DM: Data on apheresis, blood collection, and transfusion-related activities: Statistical analyses of the American Association of Blood Banks institutional membership questionnaires. Transfusion 36:375-381, 1996.
30. Love LJ, Schimpff SC, Schiffer CA, Wiernik PH: Improved prognosis for granulocytopenic patients with gram-negative bacteremia. Am Med 68:643-648, 1980.
31. Hughes WT, Armstrong D, Bodey GP, et al.: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 171:381-396, 1990.
32. Adachi N, Hasiyama M, Matsuda I: Recombinant human G-CSF and aztreonam as prophylaxis against infection in neutropenic children (letter). Lancet 337:1174, 1991.
33. Herrmann F, Schulz G, Weiser M, et al.: Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. Am J Med 88: 619-624, 1990.
34. Wolff SN, Fay JW, Herzig H, et al.: High-dose weekly intravenous immunoglobulin to prevent infection in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. Ann Intern Med 118:937-944, 1993.
35. Sullivan KM, Kopeck KJ, Jocom J, et al.: Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 232:705-712, 1990.
36. Hester JP, Dignani MC, Anaissie FJ, Kantarjian HM, O'Brien S, Freireich EJ: Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apheresis 10:188-193, 1995.
37. Ruthe R, Anderson B, Cunningham B, Epstein R: Efficacy of granulocyte transfusions in the control of systemic candidiasis in the leukopenic host. Blood 52:493-498, 1978.
38. Chow H, Sarpel S, Epstein R: Experimental candidiasis in neutropenic dogs: Tissue burden of infection and granulocyte transfusion effects. Blood 59:328-333, 1982.
39. Bhatia S, McCullough JJ, Perry EH, et al.: Granulocyte transfusions: Efficacy in fungal infections of neutropenic patients following bone marrow transplantation. Transfusion 34:226-231, 1994.
40. Karp DD, Ervin TJ, Turtle S, et al.: Pulmonary complications during granulocyte transfusions: Incidence and clinical features. Vox Sang 42:57-61, 1982.
41. Dutcher JP, Fox JJ, Riggs C, Johnston GS, Schiffer CA: Pulmonary retention of indium-111-labeled granulocytes in alloimmunized patients (abstract). Blood 60:177A, 1982.
42. Ungerleider RS, Applebaum FR, Trapani RJ, Deisseroth AB: Lack of predictive value of antileukocyte antibody screening in granulocyte transfusion therapy. Transfusion 19:90-94, 1979.
43. Goldstein IM, Eyre JH, Terasaki PI, Henderson ES, Graw RG Jr.: Leukocyte transfusions: Role of leukocyte alloantibodies in determining transfusion response. Transfusion 11:19-24, 1971.
44. McCullough JJ, Weiblen BJ, Clay ME, Forstrom L: Effect of leukocyte antibodies on the fate, in vivo, of indium-111-labeled granulocytes. Blood 58:164-170, 1981.
45. Dutcher JP, Schiffer CA, Johnston GS, et al.: Alloimmunization prevents the migration of transfused 111-indium-labeled granulocytes to sites of infection. Blood 62:354-360, 1983.
46. Dahlke MB, Keashen M, Alavi JB, Koch PA, Eisenstaedt R: Granulocyte transfusions and outcome of alloimmunized patients with gram-negative sepsis. Transfusion 22:374-378, 1982.
47. McCullough J, Clay M, Hurd D, et al.: Effect of leukocyte antibodies and HLA matching on the intravascular recovery, survival, and tissue localization of 111-indium granulocytes. Blood 67: 522-528, 1986.
48. Hollingshead LM, Goa KL: Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 42:300-330, 1991.
49. Kapiotis S, Quehenberger P, Eichler HG, et al.: Effect of hydroxyethylstarch on the activity of blood coagulation and fibrinolysis in healthy volunteers: comparison with albumin. Crit Care Med 22: 606-612, 1994.